Study on the HIV Status of the Children Born to HIV Positive Mothers After Prophylactic Nevirapine Therapy
Authors/Creators
- 1. Ex Consultant, Dept of Pediatrics, SMGS Hospital Govt Medical College Jammu, J & K, India
- 2. Consultant, Dept of Pediatrics, SMGS Hospital Medical College Jammu, J & K, India
Description
Introduction: HIV 1 and HIV 2 are members of the Retroviridae family and belong to the lentivirus genus. HIV infection affects the immune system and disrupts its homeostasis. In 2015, WHO estimated that 1.8 million children younger than 15 yrs. of age worldwide were living with HIV 1 infection. Children contribute to one-sixth of HIV deaths and more than 95% of HIV infections in children are due to vertical transmission. Aim: To analyze the efficacy of nevirapine prophylactic therapy in the prevention transmission of HIV infection from mother to child. Method: This retrospective cohort study was conducted at a Pediatric Centre of Excellence in HIV Care in northern India. It focused on infants born to HIV-positive mothers enrolled in the Prevention of Mother-to-Child Transmission (PMTCT) program. This study assessed HIV status using DNA-PCR and serological tests in infants before and after national guideline changes. Maternal and infant data was obtained, including nutritional status and ethical approval. Results: In a study involving 47 children born to HIV-positive mothers (25 male, 22 female), significant findings emerged. Of the mothers, 36% were identified as HIV-positive before pregnancy, 51% during antenatal testing, and 10% during labor. Notably, more mothers were identified during antenatal than prenatal and natal periods (P=0.047). Additionally, 6% of children tested positive for HIV after Nevirapine prophylaxis, with a significant number having negative results (P=0.041). Rural areas had more affected children (27) than urban areas (20). ELISA testing was conducted on 28% of children, revealing a 4% positive rate. Conclusion: The implementation of Nevirapine prophylaxis therapy showed promising results, with a low proportion of HIV infection among the children born to HIV-positive mothers.
Abstract (English)
Introduction: HIV 1 and HIV 2 are members of the Retroviridae family and belong to the lentivirus genus. HIV infection affects the immune system and disrupts its homeostasis. In 2015, WHO estimated that 1.8 million children younger than 15 yrs. of age worldwide were living with HIV 1 infection. Children contribute to one-sixth of HIV deaths and more than 95% of HIV infections in children are due to vertical transmission. Aim: To analyze the efficacy of nevirapine prophylactic therapy in the prevention transmission of HIV infection from mother to child. Method: This retrospective cohort study was conducted at a Pediatric Centre of Excellence in HIV Care in northern India. It focused on infants born to HIV-positive mothers enrolled in the Prevention of Mother-to-Child Transmission (PMTCT) program. This study assessed HIV status using DNA-PCR and serological tests in infants before and after national guideline changes. Maternal and infant data was obtained, including nutritional status and ethical approval. Results: In a study involving 47 children born to HIV-positive mothers (25 male, 22 female), significant findings emerged. Of the mothers, 36% were identified as HIV-positive before pregnancy, 51% during antenatal testing, and 10% during labor. Notably, more mothers were identified during antenatal than prenatal and natal periods (P=0.047). Additionally, 6% of children tested positive for HIV after Nevirapine prophylaxis, with a significant number having negative results (P=0.041). Rural areas had more affected children (27) than urban areas (20). ELISA testing was conducted on 28% of children, revealing a 4% positive rate. Conclusion: The implementation of Nevirapine prophylaxis therapy showed promising results, with a low proportion of HIV infection among the children born to HIV-positive mothers.
Files
IJPCR,Vol15,Issue12,Article14.pdf
Files
(412.4 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:41788225f20d0f77c7847d6039ecff79
|
412.4 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-11-19
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue12,Article14.pdf
- Development Status
- Active
References
- 1. Shah NK, Mamta M, Shah I, Deepak U, Lodha R, Pensi T, et al. Guidelines for HIV Care and Treatment in Infants and Children, 1st ed. New Delhi: NACO and IAP. 2006; 15: 3-90. 2. Shah NK. Epidemiology and Trend of HIV in India. In: Shah I, Shah NK, Manglani M, editors. IAP Speciality Series on Pediatric HIV. 1st ed. Mumbai: IPA. 2006; 20: 11-69. 3. World Health Organization, Guidelines on HIV Prevention, 2010; Treatment and Care. 4. UNAIDS. Preventing mothers from dying and babies from becoming infected by HIV. 2014; 20: 12-25. 5. Jacob SM, Anitha D, Vishwanath R, Parameshwari S, Samuel NM. The use of dried blood spots on filter paper for the diagnosis of HIV-1 in infants born to HIV seropositive women. Indian J Med Microbiol. 2008; 26: 71- 4. 6. Gbadegesin A, Adenibuyan OA, Adegbesan MA, Salu OB, Omilabu SA. Efficacy of HIV PCR techniques to diagnose HIV in infants born to HIV-infected mothers at LASUTH. Nig Q J Hosp Med. 2010; 20: 129-32. 7. Shah I. Efficacy of HIV PCR techniques to diagnose HIV in infants born to HIV-infected mothers –an Indian perspective. J Assoc Physicians India. 2006; 54: 197-9. 8. Marinda E, Humphrey JH, Iliff PJ, Mutasa K, Nathoo KJ, Piwoz EG, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. J Pediatr Infect Dis. 2007; 26: 519- 26. 9. Marazzi MC, Liotta G, Nielsen-Saines K, Haswell J, Magid NA, Buonomo E, et al. Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life. AIDS. 2010; 24: 2819-26. 10. Ugochukwu EF, Kanu SO. Early infant diagnosis of HIV infection in southeastern Nigeria: prevalence of HIV infection among HIV-exposed babies. West Afr J Med. 2010; 29: 3-7. 11. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. 2015; 26: 29-40.12. National AIDS Control Organization. Updated Guidelines for Prevention of Parent to Child Transmission of HIV using Multi Drug Antiretroviral Regimen in India. 2015; 50: 76-90. 13. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding the Kisumu Breastfeeding. Study Kenya clinical trial PLoS Med. 2011; 8: 100-1015. 14. Micek MA, Blanco AJ, Beck IA, Dross S, Matunha L, Montoya P, et al. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin Infect Dis. 2010; 50: 1405-14. 15. Palombi L, Marazzi MC, Voetberg A, Magid NA. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS IP. 2007; 21: 65-71. 16. Kourtis AP, Bulterys M. Mother-to-child transmission of HIV: Pathogenesis, mechanisms and pathways. Clin Perinatol. 2010; 37: 721-37. 17. Kourtis AP, Lee FK, Ebrams EJ, Jamieson DJ, Buttery M. Mother to child transmission of HIV: Timing and implications for prevention. Lancet Infect Dis. 2006; 6: 726-32. 18. Watts DH. Drug therapy: Management of human immunodeficiency virus infection in pregnancy. N Engl J Med. 2002; 346: 1879-91. 19. Mor Z, Chemtob D, Pessach N, Nitzan-Kaluski D. Human immunodeficiency virus in newborn of infected mothers: Pregnancy, breastfeeding and prevention. Harefuah. 2006; 145: 682-6. 20. UNAIDS. UNAIDS announces that the goal of 15 million people on life-saving HIV treatment has been met nine months ahead of schedule. 2015; 80: 70-90. 21. United Nations General Assembly. Declaration of commitment on HIV/AIDS: Five years later. Follow-up to the outcome of the twenty-sixth special session: Implementation of the declaration of commitment on HIV/ AIDS. Report of the Secretary General. 2015; 22: 100-107. 22. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331: 1173-80. 23. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 INDIAN PEDIATRICS 751 VOLUME 52__SEPTEMBER. 15, 2015. 24. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. 2019; 54: 71-80. 25. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach Geneva. 2019; 32: 67-89. 26. World Health Organization. Programmatic Update: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. 2019; 54: 55-70. 27. National AIDS Control Organization. Updated Guidelines for Prevention of Parent to Child Transmission of HIV using multi drug antiretroviral regimen in India. 2019; 18: 44-56. 28. Baijal N, Seth A, Singh S, Sharma G, Kumar P, Chandra J. HIV-free survival at the age of 18 months in children born to women with HIV infection: A retrospective cohort study. IP. 2020; 57: 34-8. 29. Powis K, Smeaton L, Fawzi W, Ogwu A, Machakaire E, Souda S, et al. In utero HAART exposure is associated with decreased growth among HIV-exposed uninfected breast-fed infants in Botswana. In Proceedings of 5th International Workshop on HIV Pediatrics, Kuala Lumpur, Malaysia. 2013 June 28-29. 30. Bhatta C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother. 2008; 61: 8-12 31. Chikhungu LC, Bispo S, Rollins N, Siegfried N, Newell ML. HIV-free survival at 12-24 months in breastfed infants of HIV-infected women on antiretroviral treatment. Trop Med Int Health. 2016; 21: 820-8.